文献速递产科母胎医学

有早发型重度子痫前期病史并接受低分子肝素预防的孕妇的血管生成因子谱

Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis.
PubMed 文献 · Obstet Gynecol · 2018-01-01

本研究为Heparin-Preeclampsia试验的计划性辅助研究,纳入有早发型重度子痫前期病史孕妇185例,随机接受低分子肝素联合阿司匹林或单用阿司匹林。两组不良复合结局相似,各孕周血管生成因子水平均无显著差异。结论认为自孕14周前开始的预防性低分子肝素治疗未改善血管生成因子谱。

要点

  • 低分子肝素联合阿司匹林组与单用阿司匹林组不良复合结局分别为38.0%与38.7%,无显著差异。
  • 两组在各孕周窗口的sFlt-1、PlGF和sEng水平均无显著差异。
  • 发生不良复合结局者在孕10-13 6/7周即出现血管生成因子谱改变。

核心结论

  • 自孕14周前开始的预防性低分子肝素联合阿司匹林治疗与血管生成因子谱改善无关,这可能为近期试验中缺乏临床获益提供分子解释。

研究设计与样本

  • Heparin-Preeclampsia随机试验的计划性辅助研究,纳入有早发型重度子痫前期(小于34周)病史的孕妇,所有孕妇均接受阿司匹林后随机接受低分子肝素或单用阿司匹林。
  • 共185例患者有可用样本:低分子肝素联合阿司匹林组92例,单用阿司匹林组93例。
  • 在孕10-13 6/7周、14-17 6/7周、18-21 6/7周、22-25 6/7周、26-29 6/7周、30-33 6/7周和34-37 6/7周孕周窗口采用免疫测定法检测血清可溶性fms样酪氨酸激酶-1、胎盘生长因子和可溶性内皮糖蛋白水平。

主要发现

  • 两组基线特征相当,不良复合结局相似:低分子肝素联合阿司匹林组35/92(38.0%) vs 单用阿司匹林组36/93(38.7%),P=.92。
  • 无论孕周时段如何,接受低分子肝素联合阿司匹林者与单用阿司匹林者相比,血清可溶性fms样酪氨酸激酶-1、胎盘生长因子和可溶性内皮糖蛋白水平均无显著差异。
  • 在小于34周发生不良复合结局的孕妇中,早在孕10-13 6/7周即出现血清血管生成因子谱的显著改变,且在分娩前6-8周最为显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether daily low-molecular-weight (LMW) heparin prophylaxis during pregnancy alters profile of circulating angiogenic factors that have been linked with the pathogenesis of preeclampsia and fetal growth restriction. METHODS: This is a planned ancillary study of the Heparin-Preeclampsia trial, a randomized trial in pregnant women with a history of severe early-onset preeclampsia (less than 34 weeks of gestation). In the parent study, all women were treated with aspirin and then randomized to receive LMW heparin or aspirin alone. In this study, we measured serum levels of circulating angiogenic factors (soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin by immunoassay) at the following gestational windows: 10-13 6/7 weeks, 14-17 6/7 weeks, 18-21 6/7 weeks, 22-25 6/7 weeks, 26-29 6/7 weeks, 30-33 6/7 weeks, and 34-37 6/7 weeks. RESULTS: Samples were available from 185 patients: LMW heparin+aspirin (n=92) and aspirin alone (n=93). The two groups had comparable baseline characteristics and had similar adverse composite outcomes (35/92 [38.0%] compared with 36/93 [38.7%]; P=.92). There were no significant differences in serum levels of soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin in the participants who received LMW heparin and aspirin compared with those who received aspirin alone regardless of gestational age period. Finally, women who developed an adverse composite outcome at less than 34 weeks of gestation demonstrated significant alterations in serum angiogenic profile as early as 10-13 6/7 weeks that was most dramatic 6-8 weeks preceding delivery. CONCLUSION: Prophylactic LMW heparin therapy when beginning from before 14 weeks of gestation with aspirin during pregnancy is not associated with an improved angiogenic profile. This may provide a molecular explanation for the lack of clinical benefit noted in recent trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00986765.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lecarpentier E, Gris JC, Cochery-Nouvellon E, et al. Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis. Obstet Gynecol. 2018. PMID: 29215518. doi:10.1097/AOG.0000000000002380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。